incretin mimetics glp 1 agonists Incretins: How we got here, where we're at and what is coming next Incretin Therapeutics in the Management

Periodic body composition assessmentwhere feasiblemay therefore help contextualize total weight reduction relative to lean mass preservation

Sulfonylureas Current evidence demonstrates significant heterogeneity in the effects of sulfonylureas on cancer risk

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm2018 executive summary

Table 2: Summary of anaesthetic-related recommendations and considerations for case management to reduce risks of aspiration

doi: 10.1037/amp0000059 [DOI] [PMC free article] [PubMed] [Google Scholar] 149.Volkow ND